Background: Long-term prognosis of patients with chronic hepatitis C infection (HCV) remains incompletely characterized. We investigated the long-term prognosis of liver disease in patients with chronic HCV infection who have not received antiviral therapy.
| INTRODUCTION
Approximately 180 million individuals worldwide are chronically infected with hepatitis C virus (HCV). It is a common cause of chronic liver disease and hepatocellular carcinoma (HCC) in Japan, the United States, and many European countries. 1, 2 Chronic infection with HCV is a major cause of progressive liver damage and long-term sequelae such as cirrhosis and HCC.
Interferon (IFN)-based therapy has been performed to treat HCV patients with chronic hepatitis or decompensated cirrhosis. There have been many reports that IFN-based therapy is useful for reducing serum alanine aminotransferase (ALT) levels, clearing HCV RNA, and improving the liver fibrosis in patients with chronic HCV infection. [3] [4] [5] [6] [7] Elimination of HCV has also been reported to decrease the occurrence of HCC. 6, 8 In other words, IFN-based therapy evidently decreases the incidence of liver disease-related mortality and prolongs life expectancy. [9] [10] [11] Direct-acting antivirals (DAAs) have recently been developed to treat chronic HCV infection.
They have resulted in higher rates of sustained virological response (SVR), shorter and simpler regimens, and minimal treatment-related side effects. Many patients with chronic HCV infection, including asymptomatic carriers as well as patients with chronic hepatitis and decompensated cirrhosis, have recently received DAA therapy and achieved SVR in Japan. [12] [13] [14] However, the long-term prognosis of patients with chronic HCV infection, especially asymptomatic carriers, remains incompletely characterized. Therefore, clarifying the natural history of chronic HCV infection in asymptomatic carriers is important for estimating the benefits of DAA-based therapy.
Markov chain models are useful for simulating the natural history of chronic diseases. 15, 16 Disease states obtained from patients are individually determined and incorporated into a system of transitional probabilities from 1 state to another inside of a cycle (generally lasting 1 year).
In the present study, we simulated the long-term prognosis of liver disease in chronic HCV patients who did not receive antiviral therapy using the Markov chain model. (5) HCC surveillance performed during the followup period; (6) follow-up duration greater than 3 years from the first visit; (7) no incidence of HCC for at least 1 year after the first visit; and (8) complete clinical data. Of these 2743 patients, 1011 patients received IFN-based therapy and the remaining 1732 patients did not receive IFN-based therapy during the follow-up period. Of the 1011 patients who received IFN-based therapy, 439 patients started this therapy at the start of follow-up. The remaining 572 patients received IFN-based therapy later during the follow-up period; their clinical data before the start of IFN-based therapy was used for analysis. Consequently, 2304 patients 
| MATERIALS AND METHODS

| Patients
| HCV RNA and genotype were confirmed using PCR
At our institution, the decision to offer IFN-based therapy to patients with chronic HCV infection was determined based on the clinical guidelines. [19] [20] [21] The 1732 patients who did not receive IFN-based therapy for chronic HCV infection had no indications for IFN-based therapy or declined treatment. If a patient with an indication for IFNbased therapy declined after being provided with sufficient information about the treatment, they received hepatoprotective medications (eg, ursodeoxycholic acid) as an alternative therapy.
| HCC surveillance
HCC surveillance was conducted every 3 to 6 months. It included ultrasonography and blood tests, including measurement of the tumor marker α-fetoprotein according to the Clinical Practice Guidelines for Hepatocellular Carcinoma in Japan. 22 If a nodular lesion was detected by ultrasonography or a tumor marker was found to be elevated, additional imaging studies (computed tomography, magnetic resonance imaging, or both) were performed. The diagnosis of HCC was based on imaging characteristics specified by the guidelines of the American Association for the Study of Liver Diseases. 23,24
| Disease states and diagnosis of liver
In the present study, we decided disease states of liver as asymptomatic carrier, chronic hepatitis, cirrhosis, and HCC. Disease states were defined according to the following criteria 25, 26 :
(1) Asymptomatic carrier: ALT less than 35 IU/L and absence of liver cirrhosis;
(2) Chronic hepatitis: ALT or more 35 IU/L and absence of liver cirrhosis;
(3) Cirrhosis: FIB-4 index > 3.25 17, 18 ; and 3. HCC was assumed to be an absorbing state, defined as having no later transitions to other liver disease states.
4.
1-year transition probability estimates were stratified by age and sex.
Annual transition probabilities for each state of liver were analyzed according to sex and 10-year age groups. Next, the initial starting conditions were specified as asymptomatic carrier and chronic hepatitis at age 40. The % probabilities for transition crosswise liver states for the following 40 years were simulated according to yearly transition probability processions in the study patients, stratified by sex.
| Statistical methods
Quantitative data are expressed as median values (interquartile range). Data analysis was carried out by JMP (version 9, SAS Institute, Cary, NC). Table 1 shows the baseline characteristics of the study patients. The (Table 2 ). Table S1 also shows the number of liver disease states at the start of follow-up among study patients stratified by sex and 10-year age group. During follow-up, 473 patients developed HCC. The median follow-up was 10.7 (6.7-15.0) years.
| RESULTS
| Characteristics of patients
| 1-Year disease state of liver transition probability processions
The 1-year disease state of liver transition probabilities in the four disease states of liver were analyzed according to 20 140 PY units. Table 2 shows the 1-year disease state of liver transition probability processions in the study patients according to sex and 10-year age group.
In male asymptomatic carriers, progression to chronic hepatitis was observed in 12% to 14% over all age groups. In male patients with chronic hepatitis, progression to cirrhosis was observed mostly in the 60 to 69 (7.6%) and ≥70 age groups (9.6%). In male patients with cirrhosis, HCC development was observed in the 40 to 49 (4.4%), 50 to 59 (4.2%), 60 to 69 (4.9%), and ≥70 age groups (4.8%).
In female asymptomatic carriers, progression to chronic hepatitis was observed in 6% to 14% over all age groups. In female patients with chronic hepatitis, progression to cirrhosis was observed mostly in the 60 to 69 (8.7%) and ≥70 age groups (7.4%). In female patients with cirrhosis, HCC development was observed in the 50 to 59 (0.9%), 60 to 69 (2.7%), and ≥70 age groups (3.3%).
3.3 | Simulation of the % probabilities for transition crosswise states of liver in asymptomatic carriers at age 40 by the Markov chain model
The asymptomatic carrier state at age 40 was the primary starting state for simulation over following 40 years. In both male ( Figure 3a) and female (Figure 3b ) patients, the probability of developing chronic hepatitis gradually increased with age until the 50 seconds. The probability of developing cirrhosis gradually increased with age until 70 seconds. The probability of developing HCC increased gradually with age. The probability of HCC was higher in male vs female patients in the same age group. In male patients, the probability of HCC was higher than the probability of cirrhosis by age 80.
Conversely, in female patients, the probability of HCC was lower than the probability of cirrhosis by age 80. female patients, the probability of HCC gradually increased with age starting in the 50 seconds. In male patients, the probability of HCC was higher than the probability of cirrhosis by age 70. Conversely, in female patients, the probability of HCC was lower than the probability of cirrhosis across all age groups. with post-transfusion hepatitis, 28 blood donors, 30 drug abusers, 31 and women vaccinated with contaminated immunoglobulins. 27, 34 Therefore, the natural history of the chronic HCV infection remains incompletely characterized. Although our study was retrospective in nature, we clarified the natural history of chronic HCV infection in patients with chronic hepatitis as well as asymptomatic carriers at the start of follow-up. The advantage of our study compared with previous reports was that we estimated the long-term prognosis of liver disease in patients with persistent HCV infection over 40 years.
| DISCUSSION
Intervention in the form of DAA therapy to eradicate HCV is necessary even in asymptomatic carriers in view of the long-term natural history of persistent HCV infection.
Recent years, various laboratory scoring systems of fibrosis have
been developed in patients with chronic liver disease. 17, 18, [37] [38] [39] [40] Vallet-Pichard et al 18 18 Additionally, previous studies have reported that older age, male sex, lower albumin levels and platelet count, and elevated ALT, AST, and α-fetoprotein levels are significant risk factors for cirrhosis and HCC. [41] [42] [43] [44] [45] [46] The FIB-4 index is assessed using age, AST, ALT, and platelet count. In other words, the FIB-4 index is considered to be a more complex scoring system for evaluating the incidence of liver-related events in patients with chronic HCV infection.
The Markov model assesses data measured repeatedly with general outcomes. These types of styles explain how a transition of patient between a course of states of disease over long-term periods, which is likeable in the explanation of processes of disease that certainly include progression across stages of advancing severity. 47 In the present study, we analyzed the Markov chain model to estimate the 1-year disease state of liver transition probabilities in four disease states of liver (ie, asymptomatic carrier, chronic hepatitis, cirrhosis, and HCC) in patients with the asymptomatic carrier state, chronic hepatitis, or cirrhosis who did not receive IFN-based therapy. Particularly, we analyzed the % probabilities for transition crosswise liver states on the long-term periods in asymptomatic carriers and chronic hepatitis patients at age 40.
The principal limitations of the present research involve its hospital-based subjects and retrospective study. Therefore, further prospective studies with community-based subjects are warranted. Another limitation was that the FIB-4 index, originally an index of liver fibrosis, can overestimate the progression of liver fibrosis because it includes age, a strongly time-dependent factor. In addition, liver cirrhosis was determined as FIB-4 index or more 3.25 in this study. Consequently, it was considered that more or less patients with significant liver fibrosis stage were determined as liver cirrhosis. Further research by imaging elastography or pathological data for the confirmation of liver cirrhosis are warranted. Further, in this study, the asymptomatic carrier was defined as patients with ALT less than 35 IU/L. Therefore, it was possible that there were some patients with chronic hepatitis even in patients who were defined as asymptomatic carrier.
In conclusion, according to the Markov chain model, poor liver disease outcomes such as the progression of liver cirrhosis or HCC are possible not only in patients with chronic hepatitis but also in patients who are asymptomatic carriers at age ≥ 40 years. Further studies are warranted to confirm these findings in other populations.
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